Akari Therapeutics Plc 8-K

What Happened
Akari Therapeutics Plc held its Annual General Meeting on June 30, 2026. Shareholders entitled to vote totaled 140,032,769,533 ordinary shares and a quorum was present. Most routine and governance proposals — including receipt of the 2025 accounts, auditor ratification, remuneration policy, and authorizations for share issuances — received shareholder approval. One notable outcome: James Neal was not re-elected to the Board and his service ended at the meeting; the Board immediately appointed Dr. Ray Prudo to the Audit Committee and named Robert Bazemore as Chair of the Compensation Committee.

Key Details

• Total shares entitled to vote: 140,032,769,533; the AGM proceeded with a valid quorum on June 30, 2026.
• Failed re-election: James Neal — votes For: 13,069,414,977; Against: 29,032,560,000; Abstain: 17,527,042,489. Board changes: Dr. Ray Prudo joined the Audit Committee; Robert Bazemore appointed Compensation Committee Chair.
• Auditor actions: Shareholders ratified BDO USA, P.C. as independent registered public accounting firm for year ending Dec 31, 2026; HaysMac LLP was re-appointed statutory auditors.
• Capital/issuance approvals: Shareholders approved authorizations allowing allotment of shares (general allotment up to nominal USD 20,000 through June 30, 2031) and approved issuances related to the ELOC Purchase Agreement and Series H/I/J warrants (covering up to 4,411,764 ADS and 117,647 placement agent ADS).

Why It Matters
Board composition and committee leadership changed immediately after the AGM, which can affect corporate governance and oversight (audit and compensation oversight in particular). The shareholder approvals for share issuances and warrants are important because they permit potential capital raises and could lead to dilution if exercised. Auditor ratification provides clarity on the firms handling Akari’s 2026 audit work. Advisory votes (e.g., on executive compensation) are non‑binding but signal shareholder sentiment. Investors should note these governance and capital-authority decisions when assessing Akari’s oversight, financing plans, and potential dilution.